Pulmatrix, Mylan to jointly develop PUR0200 for COPD
Currently, PUR0200 is being evaluated for chronic obstructive pulmonary disease (COPD) and the first small molecule formulation from Pulmatrix’s new iSPERSE inhaled dry powder technology. PUR0200, which contains
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.